GU-187: Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Neuroendocrine tumours; Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 An additional Cohort C (n=25) is added and patients with Neuroendocrine Tumors will be also enrolled in Cohorts A and C.
- 19 Sep 2024 Planned number of patients changed from 86 to 111.
- 08 Mar 2024 Number of treatment arms have been increased from 1 to 2 by the addition of Cohort B Experimental: Cabozantinib and nivolumab arm, and the study design is changed from single group to parallel. Treatment naive patients will now be included in cohort B, for which an additional primary efficacy end point is also added.